Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, H.J.[Kim, H.J.] | - |
dc.contributor.author | Noh, W.C.[Noh, W.C.] | - |
dc.contributor.author | Nam, S.J.[Nam, S.J.] | - |
dc.contributor.author | Park, B.-W.[Park, B.-W.] | - |
dc.contributor.author | Lee, E.S.[Lee, E.S.] | - |
dc.contributor.author | Im, S.A.[Im, S.A.] | - |
dc.contributor.author | Jung, Y.S.[Jung, Y.S.] | - |
dc.contributor.author | Yoon, J.H.[Yoon, J.H.] | - |
dc.contributor.author | Kang, S.S.[Kang, S.S.] | - |
dc.contributor.author | Park, K.H.[Park, K.H.] | - |
dc.contributor.author | Lee, S.-J.[Lee, S.-J.] | - |
dc.contributor.author | Jeong, J.[Jeong, J.] | - |
dc.contributor.author | Lee, M.H.[Lee, M.H.] | - |
dc.contributor.author | Cho, S.H.[Cho, S.H.] | - |
dc.contributor.author | Kim, S.Y.[Kim, S.Y.] | - |
dc.contributor.author | Kim, H.-A.[Kim, H.-A.] | - |
dc.contributor.author | Han, S.-H.[Han, S.-H.] | - |
dc.contributor.author | Han, W.[Han, W.] | - |
dc.contributor.author | Hur, M.H.[Hur, M.H.] | - |
dc.contributor.author | Kim, S.[Kim, S.] | - |
dc.contributor.author | Ahn, S.H.[Ahn, S.H.] | - |
dc.date.accessioned | 2021-12-28T14:54:35Z | - |
dc.date.available | 2021-12-28T14:54:35Z | - |
dc.date.created | 2021-09-17 | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/91950 | - |
dc.description.abstract | Background: Adding ovarian function suppression (OFS) after chemotherapy improves survival in young women with moderate- and high-risk breast cancer. Assessment of ovarian function restoration after chemotherapy becomes critical for subsequent endocrine treatment and addressing fertility issues. Patients and methods: In the adding OFS after chemotherapy trial, patients who resumed ovarian function up to 2 years after chemotherapy were randomised to receive either 5 years of tamoxifen or adding 2 years of OFS with tamoxifen. Ovarian function was evaluated from enrolment to randomisation, and patients who did not randomise because of amenorrhoea for 2 years received tamoxifen and were followed up for 5 years. Prospectively collected consecutive hormone levels (proportion of patients with premenopausal follicle-stimulating hormone [FSH] levels <30 mIU/mL and oestradiol [E2] levels ≥40 pg/mL) and history of menstruation were available for 1067 patients with breast cancer. Results: Over 5 years of tamoxifen treatment, 69% of patients resumed menstruation and 98% and 74% of patients satisfied predefined ovarian function restoration as per serum FSH and E2 levels, respectively. Menstruation was restored in 91% of patients younger than 35 years at baseline, but in only 33% of 45-year-old patients over 5 years. Among these patients, 41% experienced menstruation restoration within 2 years after chemotherapy and 28% slowly restored menstruation after 2–5 years. Younger age (<35 years) at baseline, anthracycline without taxanes and ≤90 days of chemotherapy were predictors of menstruation restoration. Conclusions: During 5 years of tamoxifen treatment after chemotherapy, two-thirds of the patients experienced menstruation restoration, especially patients younger than 35 years. Young age, Adriamycin without taxanes and short duration of chemotherapy appeared to have a positive effect on ovarian reserves in the long term. Trial registration: ClinicalTrials.gov identifier: NCT00912548. © 2021 Elsevier Ltd | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Elsevier Ltd | - |
dc.title | Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Nam, S.J.[Nam, S.J.] | - |
dc.identifier.doi | 10.1016/j.ejca.2021.03.017 | - |
dc.identifier.scopusid | 2-s2.0-85106222224 | - |
dc.identifier.wosid | 000660301100019 | - |
dc.identifier.bibliographicCitation | European Journal of Cancer, v.151, pp.190 - 200 | - |
dc.relation.isPartOf | European Journal of Cancer | - |
dc.citation.title | European Journal of Cancer | - |
dc.citation.volume | 151 | - |
dc.citation.startPage | 190 | - |
dc.citation.endPage | 200 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | MULLERIAN HORMONE-LEVELS | - |
dc.subject.keywordPlus | INDUCED AMENORRHEA | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | REMAIN PREMENOPAUSAL | - |
dc.subject.keywordPlus | ENDOCRINE THERAPY | - |
dc.subject.keywordPlus | GRANULOSA-CELLS | - |
dc.subject.keywordPlus | YOUNG-WOMEN | - |
dc.subject.keywordPlus | ANTHRACYCLINE | - |
dc.subject.keywordPlus | FERTILITY | - |
dc.subject.keywordPlus | PRESERVATION | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | E2 | - |
dc.subject.keywordAuthor | FSH | - |
dc.subject.keywordAuthor | Menstruation | - |
dc.subject.keywordAuthor | Ovarian function | - |
dc.subject.keywordAuthor | Tamoxifen | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.